Boehringer Ingelheim GmbH Logo
2016-03-08 12:10
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
  • AbbVie and Boehringer Ingelheim will share responsibility for future clinical development and establish a Joint Steering Committee
    Anti-IL-23 antibody now in Phase 3 for psoriasis demonstrated greater efficacy over ustekinumab in Phase 2 clinical studies with a potential for quarterly dosing
    Potential to become best-in-class treatment in psoriasis with additional Phase 2 development in Crohn’s disease, psoriatic arthritis and asthma; observed safety profile is consistent with the IL-23 class
    AbbVie also gains rights to an anti-CD-40 antibody currently in Phase 1 development; next steps of clinical development are led by Boehringer Ingelheim
NORTH CHICAGO, ILL. & INGELHEIM, GERMANY--(Business Wire/Korea Newswire) March 8, 2016 -- AbbVie (NYSE:ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn’s disease, psoriatic arthritis and asthma. In addition to the anti-IL-23 antibody, AbbVie gains rights to an anti-CD-40 antibody, BI 655064, currently in Phase 1 development. Boehringer Ingelheim will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the program after completion of certain undisclosed clinical achievements.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160307005807/en/

“This collaboration positions BI 655066 as AbbVie’s lead investigational compound in psoriasis, complementing our robust immunology pipeline,” said Michael E. Severino, M.D., executive vice president and chief scientific officer, AbbVie. “Our expertise in developing and commercializing the world’s leading biologic, combined with Boehringer Ingelheim’s clinical success to-date will enable us to offer patients a new treatment option with the potential to meaningfully improve the standard of care.”

“Our Immunology R&D teams have successfully brought forward compounds that have the potential to transform the way immune diseases are treated. I believe the collaboration with AbbVie is the best way to ensure broad access for patients to BI 655066 and BI 655064,” said Dr. Michel Pairet, Member of the Board of Managing Directors responsible for R&D nonclinical at Boehringer Ingelheim. “Our company remains strongly committed to establishing immunology as a core area of expertise and building our pipeline and capabilities in this important therapeutic area.”

Recent Phase 2 head-to-head study results in patients with moderate-to-severe plaque psoriasis showed that BI 655066 had greater efficacy over ustekinumab[1], a commonly used treatment for this life-impacting skin condition. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.[1] Patients also achieved this skin clearance faster (approximately eight weeks versus approximately 16 weeks) and for more than two months longer (≥ 32 weeks versus 24 weeks) than those on ustekinumab. In addition, completely clear skin (PASI 100) was maintained after nine months in nearly triple the percentage of patients on BI 655066 compared with ustekinumab (43 percent versus 15 percent).[1]

Additional data obtained from a pre-defined analysis reflecting the primary endpoint at 12 weeks is presented below[1]:
(To view the additional data, please visit http://goo.gl/KAZDO5)

P-values versus ustekinumab.

18 mg dose is one-time dose given at Week 0. All other treatments dosed at Week 0, 4 and 16; last observation carried forward analysis of Full Analysis Set

BI 655066 is administered as a subcutaneous injection and was generally well-tolerated in the 12-week treatment portion of the Phase 2 study. Serious adverse events were reported for patients in the BI 655066 18mg treatment group (7.0%) and ustekinumab group (2.5%), while there were no serious adverse events in the 90 mg and 180 mg treatment groups. One patient discontinued treatment in the BI 655066 18mg dose group. The most common adverse events across the BI 655066 treatment groups were common cold and headache, at 7.3 - 11.6% across the dose groups and 2.4 - 7.0%, respectively. The most common adverse events in the ustekinumab group were common cold, injection site pain and redness, sore throat and myalgia; each of which occurred in 5.0% of patients.

BI 655066 is in Phase 2 development for Crohn’s disease and asthma, and is about to enter Phase 2 development for psoriatic arthritis. In addition, Phase 2 data for Crohn’s disease will be presented at an upcoming medical meeting.

More than 100 million people suffer from psoriasis, a chronic, systemic, immune-mediated disease.[2] Psoriasis is a chronic skin disease of scaling and inflammation and can result in severe physical discomfort and disability.

Financial Terms
 
Under the terms of the license agreement, AbbVie will make an initial upfront payment of US$ 595 million. Boehringer Ingelheim will be eligible to receive additional development and regulatory milestone payments and royalties on net sales, the terms of which are not disclosed. In the initial period, the companies will share the responsibility for future development of BI 655066. AbbVie will be solely responsible for commercialization of BI 655066, while Boehringer Ingelheim will retain an option to co-promote the compound in asthma. The companies will also establish a joint Steering Committee for the development as well as the initial commercialization phase.

The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

About BI 655066
 
BI 655066 selectively blocks IL-23, a key protein involved in skin inflammation which has been linked to an overactive immune system, and is one of the key drivers of psoriasis.

NB: BI 655066 is not approved by regulatory authorities and its safety and efficacy is being investigated.

About BI 655064
 
BI 655064 is an antagonistic anti-CD40 antibody. The CD40-CD40L pathway may play a major role in immune disease such as lupus nephritis, Crohn’s disease and ulcerative colitis.

NB: BI 655064 is not approved by regulatory authorities and its safety and efficacy is being investigated.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

References

[1] K Papp et al. 2015. Onset and duration of clinical response following treatment with a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. 24th European Academy of Dermatology and Venereology (EADV) congress, Copenhagen, Denmark, 7-11th October 2015 [Presentation About Psoriasis. National Psoriasis Foundation website. http://www.psoriasis.org/about-psoriasis. Accessed on February 26, 2015.
[2] About Psoriasis. National Psoriasis Foundation website. http://www.psoriasis.org/about-psoriasis. Accessed on February 26, 2015.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160307005807/en/
  • Media Contact
  • Boehringer Ingelheim Contact
    Julia Meyer-Kleinmann
    Director Corporate Communications
    Boehringer Ingelheim
    +49 (6132) 77 8271
    m-kleinmann@boehringer-ingelheim.com
    or
    AbbVie Contact
    Media:
    Adelle Infante
    +1 (847) 938-8745
    Investors:
    Liz Shea
    +1 (847) 935-2211
Boehringer Ingelheim GmbH 전체 보도자료 보기
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

Boehringer Ingelheim Contact
Julia Meyer-Kleinmann
Director Corporate Communications
Boehringer Ingelheim
+49 (6132) 77 8271
m-kleinmann@boehringer-ingelheim.com
or
AbbVie Contact
Media:
Adelle Infante
+1 (847) 938-8745
Investors:
Liz Shea
+1 (847) 935-2211

이 보도자료 관련 분야

건강  제약  제휴  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.